SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+11.27%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$629M
AUM Growth
+$629M
(+9.7%)
Cap. Flow
-$333K
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
38.9%
Holding
144
New
36
Increased
32
Reduced
27
Closed
33
Top Buys
| 1 |
Gilead Sciences
GILD
|
$25.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$19.2M |
| 3 |
Amgen
AMGN
|
$18.5M |
| 4 |
BLUE
bluebird bio
BLUE
|
$11.4M |
| 5 |
GSK
GSK
|
$10.7M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$28.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$14.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$13.7M |
| 4 |
SHPG
Shire pic
SHPG
|
$11.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$10.3M |
Sector Composition
| 1 | Healthcare | 83.93% |
| 2 | Technology | 7.06% |
| 3 | Industrials | 1.82% |
| 4 | Consumer Discretionary | 1.62% |
| 5 | Financials | 1.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kura Oncology
KURA
$732M
| $6.41M | 0.88% |
351,953
+21,953
| +7% | +$400K |
|
|
SODA
27
DELISTED
SodaStream International Ltd
SODA
| $6.29M | 0.87% |
+73,762
| New | +$6.29M |
|
|
MLNT
28
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $6.25M | 0.86% |
984,492
+740,596
| +304% | +$4.7M |
|
29
Nice
NICE
$8.48B
| $6.23M | 0.86% |
60,043
-7,715
| -11% | -$801K |
|
|
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
| $6.2M | 0.85% |
1,552,846
+62,846
| +4% | +$251K |
|
31
uniQure
QURE
$954M
| $5.76M | 0.79% |
152,490
+24,890
| +20% | +$941K |
|
|
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
| $5.7M | 0.79% |
339,804
-65,196
| -16% | -$1.09M |
|
|
ADMS
33
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $5.52M | 0.76% |
213,625
-121,875
| -36% | -$3.15M |
|
|
BHVN
34
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $5.43M | 0.75% |
137,388
+6,288
| +5% | +$249K |
|
35
Spyre Therapeutics
SYRE
$1.02B
| $5.39M | 0.74% |
+509,118
| New | +$5.39M |
|
36
Visa
V
$681B
| $5.35M | 0.74% |
40,401
| – | – |
|
37
Ascendis Pharma
ASND
$12.1B
| $5.19M | 0.72% |
78,048
-17,426
| -18% | -$1.16M |
|
38
Larimar Therapeutics
LRMR
$337M
| $4.91M | 0.68% |
+480,000
| New | +$4.91M |
|
|
RETA
39
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $4.76M | 0.66% |
136,044
-88,956
| -40% | -$3.11M |
|
|
AUTL
40
Autolus Therapeutics
AUTL
$383M
| $4.72M | 0.65% |
+176,045
| New | +$4.72M |
|
41
Carisma Therapeutics
CARM
$15.5M
| $4.64M | 0.64% |
+2,377,068
| New | +$4.64M |
|
42
Wabtec
WAB
$32.7B
| $4.59M | 0.63% |
+46,564
| New | +$4.59M |
|
|
WHWK
43
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $4.58M | 0.63% |
+1,103,554
| New | +$4.58M |
|
44
Leap Therapeutics
LPTX
$12M
| $4.49M | 0.62% |
499,137
+72,051
| +17% | +$648K |
|
45
Mastercard
MA
$536B
| $4.47M | 0.62% |
22,760
+6,235
| +38% | +$1.23M |
|
46
Scholar Rock
SRRK
$3.3B
| $4.43M | 0.61% |
+283,997
| New | +$4.43M |
|
|
CTIC
47
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $4.36M | 0.6% |
874,407
+40,774
| +5% | +$203K |
|
48
Cisco
CSCO
$268B
| $4.3M | 0.59% |
+100,000
| New | +$4.3M |
|
|
PVLA
49
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $4.27M | 0.59% |
842,632
+42,632
| +5% | +$216K |
|
|
EPZM
50
DELISTED
Epizyme, Inc
EPZM
| $4.16M | 0.57% |
+307,154
| New | +$4.16M |
|